The disastrous Valeant document everyone's been waiting for is finally here
Reuters
After months of delays, a Senate hearing, and a precipitous stock fall, Valeant Pharmaceuticals finally filed its annual 10-K report to the Securities and Exchange Commission on Friday morning.
The document has been delayed multiple times as the company reviewed financial documents related to a specialty pharmacy, Philidor, associated with the company.
In its report, the company disclosed risk factors related to its accounting practices and new sales arrangements as... Читать дальше...